Nevertheless, updated data of the Transcend CLL04 study displayed an ORR of 82% with 45% of CR for CD19-targeting CAR T cells as single agent, resulting in a high rate of undetectable minimal residual disease (uMRD) in heavily pre-treated, high-risk CLL patients, including those refractory to both BTK inhibitors and venetoclax (78). This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.